What do the final FY26 numbers reveal about the business?

Consolidated net profit fell 30% to ₹259.23 crore while revenue contracted 12% to ₹1,054.89 crore. Profit declined much faster than sales, indicating significant margin pressure during the year.

Why is the company paying a dividend after such a poor year?

The board recommends a final dividend of ₹7.55 per share. The payout is modest and signals the company is not in emergency cash-preservation mode, despite the weaker earnings.

Are these numbers preliminary or audited?

The results are audited, meaning they are the final, verified figures for the fiscal year. They form the official record and are the basis for future performance comparisons.

What is the significance of the board changes?

Mrs. Ekta Gupta has been formally appointed as an independent director for a five-year term. The company also named new internal and cost auditors for the coming fiscal year, which is a routine governance update.

Earnings · Pharmaceuticals · Mid cap

Concord Biotech's profit falls 30% on a 12% revenue slide

Full-year audited numbers show margin pressure, but the board still proposes a dividend of ₹7.55 per share.

— 3 earlier stories on Concord Biotech Ltd. →

CONCORDBIO By Tipsheet Editorial 29 May 2026 · 8:39 PM IST Verify on BSE · NSE

Mkt cap₹12,570 cr

P/E48.18×

ROE20.50%

Debt / eq.0.00

Div yld0.63%

₹259.23 cr FY26 consolidated net profit, down 30% year-on-year.

What's new

FY26 net profit dropped 30% to ₹259.23 crore; revenue fell 12% to ₹1,054.89 crore.
Board recommends a final dividend of ₹7.55 per share despite the earnings decline.
Mrs. Ekta Gupta appointed as independent director for five years; new auditors named.

Why this matters

These audited results set the official baseline for the next valuation cycle. A 30% profit decline on a 12% revenue drop confirms costs did not scale down in line with the top line. The dividend is a signal, but not a large one.

What we're watching

Whether the margin compression is a one-off or the new normal.
Management's explanation for the 12% revenue contraction.
How the new independent director and auditor appointments play into governance.

The full read

Concord Biotech's audited FY26 results confirm a rough year. Revenue fell 12% to ₹1,054.89 crore. Net profit dropped a sharper 30% to ₹259.23 crore. The gap between the two declines points to margin erosion that the company couldn't offset. The Ahmedabad-based firm still recommends a ₹7.55 per share dividend, a modest gesture that keeps some cash flowing to shareholders. Alongside the financials, the board formalized an independent director appointment and named new auditors for the coming year. The dividend isn't the story. The story is that a 12% revenue slide turned into a 30% profit collapse, and the audited numbers now set the benchmark for how the market values the business.

Questions answered

What do the final FY26 numbers reveal about the business?: Consolidated net profit fell 30% to ₹259.23 crore while revenue contracted 12% to ₹1,054.89 crore. Profit declined much faster than sales, indicating significant margin pressure during the year.
Why is the company paying a dividend after such a poor year?: The board recommends a final dividend of ₹7.55 per share. The payout is modest and signals the company is not in emergency cash-preservation mode, despite the weaker earnings.
Are these numbers preliminary or audited?: The results are audited, meaning they are the final, verified figures for the fiscal year. They form the official record and are the basis for future performance comparisons.
What is the significance of the board changes?: Mrs. Ekta Gupta has been formally appointed as an independent director for a five-year term. The company also named new internal and cost auditors for the coming fiscal year, which is a routine governance update.

Mentioned: FY26 · ₹1,054.89 cr revenue · ₹7.55 dividend per share

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on CONCORDBIO →

29 May 2026 · 8:39 PM IST Concord Biotech's profit falls 30% on a 12% revenue slide
1d ago Concord Biotech wins USFDA nod for generic transplant drug
5d ago Concord Biotech profit drops 30% on 11% revenue fall
5d ago Concord Biotech profit falls 30% as revenue shrinks in FY26